FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma
- 44 Downloads
Epidermal growth factor receptor (EGFR) gene is frequently mutated in non-small cell lung cancer (NSCLC), which can be targeted by EGFR tyrosine kinase inhibitors (TKIs). It is hard, however, to monitor the performance of EGFR-TKI therapy dynamically. Therefore, therapeutic indicators are urgently needed. Novel antibody microarray, containing 41,472 antibodies, was used for comprehensive analyzing of serum samples from 9 normal subjects and 9 EGFR mutated lung adenocarcinoma patients at three EGFR-TKI treatment time points, including before treatment (Baseline), partial response (PR) during treatment, and disease progression (PD) after resistance. Through microarray data analysis, five candidate antibodies were screened out for confirmation in serum samples and the verified one was utilized for candidate protein identification through immunoprecipitation-mass spectrometry strategy. A novel protein, isoform 2 of fibrinogen alpha chain (FGA2), was revealed and verified in the discovery sample set. Its performance as therapy indicator was further evaluated in another pre-validation sample set (n = 60). Our data confirmed that serum FGA2 level was correlated with EGFR-TKI response (p < 0.05). The expression and secretion of FGA2 in hepatocytes were inhibited by EGFR-TKI, partially explaining the downregulation of FGA2 in serum. Our results demonstrate that FGA2 is an indicator of targeted therapy for EGFR mutated lung adenocarcinoma.
Antibody microarray was coupled with mass spectrometry for proteomics research.
FGA2 was discovered as an indicator of EGFR-TKI targeted therapy.
FGA2’s expression/secretion in hepatocytes was dramatically inhibited by EGFR-TKI.
KeywordsLung adenocarcinoma Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) Targeted therapy Isoform 2 of fibrinogen alpha chain Antibody microarray
H.X. and X.M.N. contributed to the study design. Z.S., X.M.N., and K.W.Z. contributed to cell culture and sample collection. Z.S. conducted the experiments and collected the data. X.M.N. and K.W.Z. collected the clinical data. Z.S., X.M.N., K.W.Z., Z.Q., S.L., X.T.J., C.X.C., S.L., and H.X. contributed to the data analysis. The manuscript was written by Z.S., X.M.N., K.W.Z., and H.X. All the authors reviewed the manuscript. All aspects of the study were supervised by H.X. and S.L.
This work was supported by grants from the National Natural Science Foundation of China (Nos. 21675110, 81972187, 31727801, 21305087, and 81302005), National Key Research and Development Program (Nos. 2017YFC1200204 and 2016YFC1303300), Projects of the Committee of Shanghai Science and Technology (Nos. 14DZ0501200, 15142200300, and 19ZR1449800), Clinical Research Project of Shanghai Municipal Public Health Bureau (No. 201840122), Advanced Appropriate Technology Promotion Project of Shanghai Municipal Public Health Bureau (No. 2019SY048), Research Project of Shanghai Municipal Cadre Health Bureau (No. 2017(12)), Doctoral Innovation Fund of Shanghai Jiao Tong University School of Medicine (No. BXJ201952), and Interdisciplinary Program of Shanghai Jiao Tong University (Nos. YG2014QN21, YG2015MS48, and YG2017MS80). H.X. is supported by the Recruitment Program of Global Youth Experts of China and National High-tech R&D Program of China (863 Program, No. 2014AA020545). X.M.N is supported by “Shanghai Young Physician Development Program” of Shanghai Municipal Public Health Bureau (No. 2012(105)).
Compliance with ethical standards
The current study adhered to the tenets of the Declaration of Helsinki and was performed after approval by the Institutional Review Board (IRB) of Shanghai Chest Hospital (IRB#KS1753 approved by Shanghai Chest Hospital Ethics Committee). All patients signed the IRB-approved written informed consents and were further enrolled for this study, allowing for the collection and analysis of blood samples. Serum samples from healthy control subjects were collected randomly from physical examination center of the Henan Provincial People’s Hospital (IRB#M15017 approved by Bio-X Ethics Committee of Shanghai Jiao Tong University). All control subjects provided written informed consents and had no history of any cancer.
Conflict of interest
The authors declare that they have no competing interests.
- 4.Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefGoogle Scholar
- 5.Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY et al (2007) Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2:430–439CrossRefGoogle Scholar
- 7.Khozin S, Blumenthal GM, Jiang X, He K, Boyd K, Murgo A, Justice R, Keegan P, Pazdur R (2014) U.S. Food and Drug Administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist 19:774–779CrossRefGoogle Scholar
- 10.Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS (2017) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18:1454–1466CrossRefGoogle Scholar
- 13.Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388CrossRefGoogle Scholar
- 14.Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W (2012) HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2:922–933CrossRefGoogle Scholar
- 16.Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109:E2127–E2133CrossRefGoogle Scholar
- 17.Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73. https://doi.org/10.1371/journal.pmed.0020073 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DT (2012) Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics 11(M111):012112. https://doi.org/10.1074/mcp.M111.012112 CrossRefPubMedGoogle Scholar
- 22.Sutandy FX, Qian J, Chen CS, Zhu H (2013) Overview of protein microarrays. Curr Protocols Protein Sci Chapter 27: Unit 27.21. DOI Google Scholar
- 26.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefGoogle Scholar